Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/131449
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: High-throughput imaging assay for drug screening of 3D prostate cancer organoids
Author: Choo, N.
Ramm, S.
Luu, J.
Winter, J.M.
Selth, L.A.
Dwyer, A.R.
Frydenberg, M.
Grummet, J.
Sandhu, S.
Hickey, T.E.
Tilley, W.D.
Taylor, R.A.
Risbridger, G.P.
Lawrence, M.G.
Simpson, K.J.
Citation: Slas Discovery, 2021; 26(9):1107-1124
Publisher: SAGE Publications
Issue Date: 2021
ISSN: 2472-5552
2472-5560
Statement of
Responsibility: 
Nicholas Choo, Susanne Ramm, Jennii Luu, Jean M. Winter, Luke A. Selth, Amy R. Dwyer … et al.
Abstract: New treatments are required for advanced prostate cancer; however, there are fewer preclinical models of prostate cancer than other common tumor types to test candidate therapeutics. One opportunity to increase the scope of preclinical studies is to grow tissue from patient-derived xenografts (PDXs) as organoid cultures. Here we report a scalable pipeline for automated seeding, treatment and an analysis of the drug responses of prostate cancer organoids. We established organoid cultures from 5 PDXs with diverse phenotypes of prostate cancer, including castrate-sensitive and castrate-resistant disease, as well as adenocarcinoma and neuroendocrine pathology. We robotically embedded organoids in Matrigel in 384-well plates and monitored growth via brightfield microscopy before treatment with poly ADP-ribose polymerase inhibitors or a compound library. Independent readouts including metabolic activity and live-cell imaging-based features provided robust measures of organoid growth and complementary ways of assessing drug efficacy. Single organoid analyses enabled in-depth assessment of morphological differences between patients and within organoid populations and revealed that larger organoids had more striking changes in morphology and composition after drug treatment. By increasing the scale and scope of organoid experiments, this automated assay complements other patient-derived models and will expedite preclinical testing of new treatments for prostate cancer.
Keywords: PARP inhibitor
high-content imaging
organoids
patient-derived xenograft
prostate cancer
Description: First Published June 11, 2021
Rights: © The Author(s) 2021. Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
DOI: 10.1177/24725552211020668
Grant ID: http://purl.org/au-research/grants/nhmrc/1102752
http://purl.org/au-research/grants/nhmrc/1138242
http://purl.org/au-research/grants/nhmrc/1156570
http://purl.org/au-research/grants/nhmrc/1186647
Appears in Collections:Aurora harvest 8
Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_131449.pdfPublished version7.8 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.